AZD3514 is a potent and oral androgen receptor with Ki of 2.2 μM and has ability of reducing AR protein expression.

AZD-3988 is a potent and selective diacylglycerol acyltransferase (DGAT-1) inhibitor (IC50 = 0.6 nM).

AZD4017 is a potent, selective, and orally bioavailable human 11β-HSD1 with IC50 of 7 nM, shows no significant activity against 11β-HSD1 and 17β-HSD1, 17β-HSD3 (IC50>30 uM).

AZD4320 is a BH3 mimetic and dual Bcl-2/Bcl-XL inhibitor with IC50 of <1 nM.

AZD4573 is a CDK9 inhibitor with an IC50 of <3 nM extracted from patent US 20160376287 A1, example 14.

AZD-4818 is a highly potent, selective CCR1 antagonist with pIC50 of 8.6, inhibits chemotaxia of human monocytes to MIP-1α in a concentration-dependent manner.

AZD-5069 is a potent and selective CXCR2 antagonist with the potential to inhibit neutrophil migration into the airways in patients with COPD.

AZD5153 6-Hydroxy-2-naphthoic acid is the 6-Hydroxy-2-naphthoic acid of AZD5153. AZD5153 is a potent, selective, and orally available BET/BRD4 bromodomain inhibitor; disrupts BRD4 with an IC50 of 1.7 nM.

AZD5153 is a potent bivalent triazolopyridazine based Bromodomain and Extraterminal (BET) Inhibitor.

AZD-5248 is a potent, selective, first generation, oral inhibitor of dipeptidyl peptidase 1 (DPP1)..

AZD5576(AZD 5576) is a potent, highly selective, and orally bioavailable inhibitor of CDK9 with IC50 of < 5 nM, decreases phosphorylation of Ser2-RNAPII in cells with an IC50 of 96 nM.

AZD-5597 is potent CDK inhibitor with in vitro anti-proliferative effects against a range of cancer cell lines.

AZD5718 (AZD-5718, AZD 5718) is a novel potent 5-lipoxygenase activating protein (FLAP) inhibitor with binding IC50 of 6.3 nM; exhibits LTB4 inhibition in human whole blood assays with IC50 of 39 nM; reduce the production of pro-inflammatory and vasoactive leukotrienes both in vitro and in vivo.

AZD-5718 is an orally available small molecule, 5-lipoxygenase activating protein (FLAP) inhibitor..

AZD5904 (AZD-5904) is a potent, selective irreversible, orally bioavailable myeloperoxidase (MPO) inhibitor with IC50 of 140 nM, similar potency in mouse and rat.

AZD6088 (AZD-6088) is a potent and selective, orally bioavailable partial agonist of the M1 muscarinic receptor, reduces heat hyperalgesia in SNL rats with an EC50 of 46.6 nM..

AZD-7325 is a potent, α2/3 functionally selective, partial GABAA receptor modulator with pKi of 9.51.

AZD7507 (AZD-7507) is a potent, selective, orally available CSF-1R (c-FMS) with IC50 of 32 nM.

AZD-7594 (AZ-13189620) is a potent, nonsteroidal, selective glucocorticoid receptor modulator (SGRM) with binding IC50 of 0.9 nM, shows no affinity for AR, PR, MR and ERα/β.

AZD-7986(Brensocatib) is a highly potent, reversible, and selective DPP1 inhibitor with enzyme and cell pIC50 of 8.4.

AZD-8165 is a potent, selective and oral thrombin inhibitor for treatment of thrombosis..

AZD-8309 (AZD8309) is a potent and orally bioavailable CXCR2 antagonist that has been proposed to regulate the transmigration of neutrophils.